Janux Therapeutics (JANX) Operating Margin (2021 - 2026)
Janux Therapeutics (JANX) reported Operating Margin of 916.5% for Q1 2026, down 159.99% quarter-over-quarter from 352.51% in Q3 2025.
Janux Therapeutics (JANX) Operating Margin (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 6 years of Operating Margin data on file, last reported at 916.5% in Q1 2026.
- Operating Margin for Q1 2026 came in at 916.5%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 1143.11% (up 7351.0% YoY), and the FY2025 annual result was 1576.67%, down 64309.0% from the prior year.
- Operating Margin fell to 916.5% in Q1 2026 per JANX's latest filing, from 352.51% in the prior quarter.
- Over five years, Operating Margin peaked at 155.36% in Q2 2024 and troughed at 8164.46% in Q3 2024.
- A 5-year average of 1434.96% and a median of 852.23% in 2022 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin tumbled 753622 bps in 2024, then soared 781195 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 642.04% in 2022, then decreased by 2 bps to 655.71% in 2023, then sank by 1145 bps to 8164.46% in 2024, then surged by 96 bps to 352.51% in 2025, then sank by 160 bps to 916.5% in 2026.
- Business Quant data shows JANX's Operating Margin at 916.5% in Q1 2026, 352.51% in Q3 2025, and 8164.46% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -916.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -916.50% |
| Sep 30, 2025 | -352.51% |
| Sep 30, 2024 | -8,164.46% |
| Jun 30, 2024 | -155.36% |
| Mar 31, 2024 | -1,610.30% |
| Dec 31, 2023 | -655.71% |
| Sep 30, 2023 | -628.25% |
| Jun 30, 2023 | -1,962.91% |
| Mar 31, 2023 | -990.28% |
| Dec 31, 2022 | -642.04% |
| Sep 30, 2022 | -994.04% |
| Jun 30, 2022 | -729.85% |
| Mar 31, 2022 | -852.23% |
| Dec 31, 2021 | -834.78% |
| Sep 30, 2021 | -940.72% |
| Jun 30, 2021 | -1,297.10% |
| Mar 31, 2021 | -601.05% |